PMID- 33224989
OWN - NLM
STAT- MEDLINE
DCOM- 20211004
LR  - 20211004
IS  - 2314-6753 (Electronic)
IS  - 2314-6745 (Print)
VI  - 2020
DP  - 2020
TI  - Type 2 Diabetes Mellitus and Chronic Heart Failure with Midrange and Preserved 
      Ejection Fraction: A Focus on Serum Biomarkers of Fibrosis.
PG  - 6976153
LID - 10.1155/2020/6976153 [doi]
LID - 6976153
AB  - As myocardial fibrosis might be an important contributor to the association of 
      diabetes mellitus with left ventricular (LV) dysfunction and chronic heart 
      failure (HF), we investigated the profile of some proinflammatory, profibrotic 
      biomarkers in patients with type 2 diabetes mellitus (T2DM) at various stages of 
      the cardiovascular disease continuum from absence of clinic since and symptoms to 
      HF with preserved (HFpEF) and midrange ejection fraction (HFmrEF). Material and 
      Methods. Sixty-two patients with T2DM (age 60 [55; 61]), 20 patients without 
      clinical manifestations of HF and 2 groups with clinical manifestations of stable 
      HF, 29 patients with HFpEF, and 13 patients with HFmrEF, were included in the 
      study. The control group consisted of 13 healthy subjects and normal BMI. All 
      patients underwent transthoracic echocardiography, laboratory assessment of 
      N-terminal fragment of the brain natriuretic peptide (Nt-proBNP), highly 
      sensitive C-reactive protein (hsCRP), soluble suppression of tumorigenesis-2 
      (sST2), galectin-3, C-terminal propeptide of procollagen type I (PICP), 
      N-terminal propeptide of procollagen type III (PIIINP), matrix 
      metalloproteinase-9 (MMP-9), and tissue inhibitor of matrix proteinase-1 
      (TIMP-1). Results. Patients with HFmrEF had higher values of LV volumetric 
      parameters, indexed parameters of LV myocardial mass (LVMM), and higher 
      concentrations of Nt-proBNP (all p < 0.05). The concentrations of galectin-3 were 
      greater in patients with HFpEF and HFmrEF compared to patients without HF (p = 
      0.01 and p = 0.03, respectively). PICP and PICP/PIIINP ratio were greater in 
      patients with HFmrEF compared to patients with HFpEF (p = 0.043 and p = 0.033, 
      respectively). In patients with T2DM and HF, a relationship was found between 
      galectin-3 and LVMM/body surface area (r = -0.58, p = 0.001), PIIINP, TIMP-1, and 
      LV end-diastolic volume (r = -0.68 and p = 0.042 and r = 0.38 and p = 0.02, 
      respectively). Conclusion. The dynamics at various stages of the cardiovascular 
      disease continuum in the serum fibrosis markers may reflect an increase in 
      fibrotic and decrease in antifibrotic processes already at the preclinical stage 
      of HF. At the same time, the changes found in the circulating procollagen levels 
      may indicate a shift in balance towards type I collagen synthesis in HFmrEF 
      compared with HFpEF.
CI  - Copyright (c) 2020 D. A. Lebedev et al.
FAU - Lebedev, D A
AU  - Lebedev DA
AUID- ORCID: 0000-0003-1808-1331
AD  - Almazov National Medical Research Centre, Saint-Petersburg, Russia.
FAU - Lyasnikova, E A
AU  - Lyasnikova EA
AUID- ORCID: 0000-0003-0613-829X
AD  - Almazov National Medical Research Centre, Saint-Petersburg, Russia.
FAU - Vasilyeva, E Yu
AU  - Vasilyeva EY
AUID- ORCID: 0000-0003-3185-3957
AD  - Almazov National Medical Research Centre, Saint-Petersburg, Russia.
FAU - Babenko, A Yu
AU  - Babenko AY
AUID- ORCID: 0000-0002-0559-697X
AD  - Almazov National Medical Research Centre, Saint-Petersburg, Russia.
FAU - Shlyakhto, E V
AU  - Shlyakhto EV
AUID- ORCID: 0000-0003-2929-0980
AD  - Almazov National Medical Research Centre, Saint-Petersburg, Russia.
LA  - eng
PT  - Journal Article
DEP - 20201107
PL  - England
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
RN  - 0 (Blood Proteins)
RN  - 0 (Galectins)
RN  - 0 (IL1RL1 protein, human)
RN  - 0 (Interleukin-1 Receptor-Like 1 Protein)
RN  - 0 (LGALS3 protein, human)
RN  - 0 (Peptide Fragments)
RN  - 0 (Procollagen)
RN  - 0 (TIMP1 protein, human)
RN  - 0 (Tissue Inhibitor of Metalloproteinase-1)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 0 (procollagen Type III-N-terminal peptide)
RN  - 0 (procollagen type I carboxy terminal peptide)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - EC 3.4.24.35 (MMP9 protein, human)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
SB  - IM
MH  - Blood Proteins
MH  - C-Reactive Protein/metabolism
MH  - Case-Control Studies
MH  - Diabetes Mellitus, Type 2/*metabolism
MH  - Diabetic Cardiomyopathies/*metabolism/physiopathology
MH  - Female
MH  - Fibrosis/blood
MH  - Galectins/blood
MH  - Heart Failure/*metabolism/physiopathology
MH  - Humans
MH  - Interleukin-1 Receptor-Like 1 Protein/blood
MH  - Male
MH  - Matrix Metalloproteinase 9/blood
MH  - Middle Aged
MH  - Myocardium/pathology
MH  - Natriuretic Peptide, Brain/blood
MH  - Peptide Fragments/blood
MH  - Procollagen/blood
MH  - *Stroke Volume
MH  - Tissue Inhibitor of Metalloproteinase-1/blood
MH  - Ventricular Dysfunction, Left/*metabolism/physiopathology
PMC - PMC7669344
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2020/11/24 06:00
MHDA- 2021/10/05 06:00
PMCR- 2020/11/07
CRDT- 2020/11/23 05:41
PHST- 2020/07/22 00:00 [received]
PHST- 2020/10/12 00:00 [revised]
PHST- 2020/10/28 00:00 [accepted]
PHST- 2020/11/23 05:41 [entrez]
PHST- 2020/11/24 06:00 [pubmed]
PHST- 2021/10/05 06:00 [medline]
PHST- 2020/11/07 00:00 [pmc-release]
AID - 10.1155/2020/6976153 [doi]
PST - epublish
SO  - J Diabetes Res. 2020 Nov 7;2020:6976153. doi: 10.1155/2020/6976153. eCollection 
      2020.